Twist Bioscience (TWST) CEO Leproust sells 49,299 shares via 10b5-1 plan

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an exercise-and-sell transaction under a pre-arranged Rule 10b5-1 trading plan. She exercised options to acquire a total of 49,299 shares of common stock at an exercise price of $8.82 per share and sold the same number of shares in open-market transactions.

The sales covered 24,282 shares at a weighted average price of $65.0789 per share, 23,752 shares at $65.2392 per share, and 1,265 shares at $66.2813 per share. After these transactions, she continues to hold 846,872 shares of Twist Bioscience common stock directly, along with remaining employee stock options, including awards exercisable into 64,950 shares at an exercise price of $67.85 per share.

Insider Trade Summary 10b5-1

Net Seller: 49,299 shares ($3,213,653)

Net Sell 11 txns

Insider Leproust Emily M.

Role Chief Executive Officer

Sold 49,299 shs ($3.21M)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	25,017	$0.00	--
Exercise	Common Stock	25,017	$8.82	$221K
Sale	Common Stock	23,752	$65.2392	$1.55M
Sale	Common Stock	1,265	$66.2813	$84K
Exercise	Employee Stock Option (right to buy)	24,282	$0.00	--
Exercise	Common Stock	24,282	$8.82	$214K
Sale	Common Stock	24,282	$65.0789	$1.58M
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 91,909 shares (Direct, null); Common Stock — 871,889 shares (Direct, null)

Footnotes (1)

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.505 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.09 to $66.72 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Net shares sold: 49,299 shares Option exercise price: $8.82 per share Sale price tranche 1: $65.0789 per share +4 more

7 metrics

Net shares sold 49,299 shares Open-market sales reported for late May 2026

Option exercise price $8.82 per share Exercise price for 49,299 common shares

Sale price tranche 1 $65.0789 per share Weighted average for 24,282 shares sold

Sale price tranche 2 $65.2392 per share Weighted average for 23,752 shares sold

Sale price tranche 3 $66.2813 per share Weighted average for 1,265 shares sold

Shares held after transactions 846,872 shares Direct Twist Bioscience common stock holding

Remaining option award 64,950 shares at $67.85 Employee stock option, expires August 31, 2030

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average sales price per share, performance stock options

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

weighted average sales price per share financial

"Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00..."

performance stock options financial

"Represents performance stock options granted to the reporting person on September 1, 2020..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leproust Emily M.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		M(1)		24,282	A	$8.82	871,154	D
Common Stock	05/26/2026		S(1)		24,282	D	$65.0789(2)	846,872	D
Common Stock	05/27/2026		M(1)		25,017	A	$8.82	871,889	D
Common Stock	05/27/2026		S(1)		23,752	D	$65.2392(3)	848,137	D
Common Stock	05/27/2026		S(1)		1,265	D	$66.2813(4)	846,872	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.95							(5)	09/28/2025	Common Stock	0		0	D
Employee Stock Option (right to buy)	$26.66							(6)	11/18/2028	Common Stock	0		266,539	D
Employee Stock Option (right to buy)	$23.33							(7)	10/23/2029	Common Stock	0		131,290	D
Employee Stock Option (right to buy)	$67.85							12/19/2022	08/31/2030	Common Stock	64,950		64,950(8)	D
Employee Stock Option (right to buy)	$8.82	05/26/2026		M		24,282		(9)	09/28/2027	Common Stock	24,282	$0	116,926	D
Employee Stock Option (right to buy)	$8.82	05/27/2026		M		25,017		(9)	09/28/2027	Common Stock	25,017	$0	91,909	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.505 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.09 to $66.72 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

6. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

7. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

8. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

9. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Twist Bioscience (TWST) CEO Emily Leproust report in this Form 4?

Emily Leproust reported option exercises and related stock sales. She exercised options for 49,299 common shares at an $8.82 exercise price and sold the same 49,299 shares in open-market transactions at weighted average prices around the mid-$60s per share.

How many Twist Bioscience (TWST) shares did the CEO sell and at what prices?

Emily Leproust sold 49,299 Twist Bioscience common shares. The transactions included 24,282 shares at a weighted average $65.0789, 23,752 shares at $65.2392, and 1,265 shares at $66.2813, as part of planned open-market sales disclosed in the filing.

How many Twist Bioscience (TWST) shares does the CEO hold after these transactions?

After the reported transactions, Emily Leproust directly holds 846,872 Twist Bioscience common shares. This figure reflects her position following the option exercises and associated open-market sales disclosed in the Form 4 filing for late May 2026.

Were the Twist Bioscience (TWST) CEO’s stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on May 27, 2025. Such pre-arranged plans execute trades automatically according to preset instructions, reducing the significance of trade timing decisions.

What stock options does the Twist Bioscience (TWST) CEO still hold after this Form 4?

The derivative holdings table shows remaining employee stock options, including an award exercisable into 64,950 common shares at a $67.85 exercise price expiring August 31, 2030, along with other options that currently show no underlying shares in this filing excerpt.

What type of insider transaction pattern does this Twist Bioscience (TWST) Form 4 show?

The filing reflects an exercise-and-sell pattern. Emily Leproust exercised options to acquire 49,299 shares at $8.82 per share, then sold the same number in open-market trades, resulting in net share sales while retaining a substantial remaining equity position.